A recent study has shown that children who previously experienced multisystem inflammatory syndrome (MIS-C), a rare COVID-19 complication, are not at risk of recurrence of their symptoms after getting the vaccine. Co-authored by Dr. Dongngan Truong, a pediatric cardiologist at University of Utah Health, the study surveyed 385 eligible children over five and found that 48% of them received the vaccine with none experiencing a recurrence of MIS-C symptoms. The side effects of the vaccine were in line with the general population, with no incidents of MIS-C recurrences or heart inflammation reported.
The study is part of the RECOVER initiative through the National Institutes of Health, aiming to study COVID-19 and track vaccinations. The bivalent vaccine was not available when the study was conducted, but so far there have been no reported issues with it. These findings provide important insights for families with children who have suffered from MIS-C, helping them make informed decisions about their health. The research team plans to continue following children who had MIS-C over the next few years to monitor their progress.